Clear Street initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $33 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with a Buy at TD Cowen
- Summit Therapeutics’ Ivonescimab: A Potential Game-Changer in NSCLC Treatment with Promising HARMONi Trial Results
- BioNTech price target lowered to $132 from $140 at Morgan Stanley
- Summit Therapeutics’ Earnings Call: Ivonescimab’s Promising Progress
- Apple reports earnings beat, China weighs trade talks with U.S.: Morning Buzz